Esperion scores FDA nod for cholesterol-buster Nexletol
Esperion has had a rocky road to approval for its LDL-cholesterol-lowering drug Nexletol after a late-stage trial in 2018 threatened to derail its quest. But after backing its drug up with strong safety data, Esperion has the green light to go to market. The FDA on Friday approved Esperion’s Nexletol (bempedoic acid) to lower LDL cholesterol… Read More »
